Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2000

View Archived Issues

Altea receives second grant for noninvasive delivery of macromolecules

Shire submits NDA for once-daily Adderall for ADHD

Sequitur licenses antisense technology to Vertex

First milestone payment received in Arena's CART research collaboration with Lilly

Procyon and Biovation enter cancer immunotherapy agreement

Theratechnologies proceeds with Pharma-G acquisition

SmithKline Beecham to purchase Block Drug

NIAID awards Sequella funding for tuberculosis research

Cephalon acquires Anesta; Anesta's Actiq receives U.K. approval

Remicade recommended for expanded approval in Europe

EMEA issues positive recommendation for Schering-Plough's desloratadine

Novazyme's enhanced-uptake enzyme replacement therapy designated orphan drug

STI-571 enhances potency of antileukemic therapies against Bcr-Abl-expressing cells

Piracetam found to enhance poststroke language recovery

CNI-H1194: a small-molecule inhibitor of nuclear translocation of HIV-1 preintegration complexes

New heterodinucleotide endowed with activity against HIV and HSV-1 in macrophages

Immunosuppressant ISAtx-247 moves steadily through clinical trials

Engineered prostate cancer-specific virus tested in patients with advanced, metastatic disease

Mechanism of potential new treatment for erectile dysfunction elucidated

NitroMed describes improved methods of treating sexual dysfunction

Series of patents issued to Merck for new protein prenyltransferase inhibitors

Selective COX-2 inhibitors with pyrazolopyridine structure in development at Glaxo Wellcome

Recent patent covers new approach to managing certain side effects of cancer therapy

Roche presents recently identified endothelin receptor antagonists

Cathepsin S inhibitors revealed by Boehringer Ingelheim along with therapeutic uses

Thyroid receptor ligands, preferably for use in obesity, claimed by Pfizer

Key patents related to its CpG-based products licensed by Coley from Isis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...